|
|
|
|
|
|
|
M T Wed Th F |
|
17 June, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
There’s been a lot of uncertainty with the FDA missing many of its top leaders. Now, the agency appears to be going back to its pre-Marty Makary and Vinay Prasad days, by allowing uniQure to file for accelerated approval in Huntington’s disease. Max Gelman has the details here. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Max Gelman
|
Regulatory flexibility appears to be back on the FDA’s menu following the departures of Marty Makary and Vinay Prasad. At the center of the... | |
|
|
|
|
|
|
by Elizabeth Cairns
|
Novo Nordisk got robbed and is in the unenviable position of being extorted by the thieves. At stake, according to a group that has claimed... | |
|
|
|
|
|
|
|
|
by Ayisha Sharma
|
The waiting list at a UK online pharmacy for Novo Nordisk’s Wegovy pill now stands at 30,000 people a week after approval, in a sign... | |
|
|
|
 |
|
AbCellera CEO Carl Hansen (L) and Jazz Pharmaceuticals' Joshua Allen |
|
|
|
by Kyle LaHucik
|
For much of its first decade, Canadian antibody developer AbCellera signed partnership after partnership, securing 40 biopharma alliances that led to more than a dozen... | |
|
|
|
|
|
|
by Lei Lei Wu
|
Triveni Bio announced a $65 million Series C after its second asset for eczema entered clinical studies last month. The Series C was co-led by... | |
|
|
|
 |
|
From L-R: executive chair Rob Lenz, CSO Leon Garcia, CEO Anurag Agarwal and CMO Ernesto Aycardi (courtesy Vedana Therapeutics) |
|
|
|
by Ayisha Sharma
|
Vedana Therapeutics has emerged from stealth with $46 million in Series A proceeds with the goal of developing treatments that could free patients from migraines... | |
|
|
|
|
|
